SG Americas Securities LLC Purchases New Shares in Kodiak Sciences Inc. (NASDAQ:KOD)

SG Americas Securities LLC acquired a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,813 shares of the company’s stock, valued at approximately $33,000.

A number of other hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC grew its stake in shares of Kodiak Sciences by 14.1% during the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock valued at $4,614,000 after buying an additional 242,559 shares during the last quarter. Vanguard Group Inc. grew its position in Kodiak Sciences by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock valued at $8,702,000 after acquiring an additional 10,978 shares during the last quarter. Renaissance Technologies LLC increased its stake in Kodiak Sciences by 21.9% in the second quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock worth $1,666,000 after purchasing an additional 127,400 shares during the period. Ikarian Capital LLC lifted its position in shares of Kodiak Sciences by 15.4% during the first quarter. Ikarian Capital LLC now owns 476,586 shares of the company’s stock worth $2,507,000 after purchasing an additional 63,705 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Kodiak Sciences by 41.6% during the second quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock valued at $391,000 after purchasing an additional 48,930 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $3.93 on Wednesday. The stock has a market cap of $206.78 million, a price-to-earnings ratio of -1.05 and a beta of 2.34. The firm’s 50-day moving average is $2.81 and its two-hundred day moving average is $2.93. Kodiak Sciences Inc. has a 1 year low of $1.38 and a 1 year high of $7.77.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. On average, equities analysts expect that Kodiak Sciences Inc. will post -3.52 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of “Hold” and an average price target of $5.00.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.